secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001628280-23-006782
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma reports 17% revenue growth to $42M in FY2022; adj. EPS $0.14
------------------------------------------------------------------------------

- FY2022 revenue $42.0M (+17% YoY); net loss $5.6M ($0.38/sh); adj. earnings $2.1M ($0.14/sh) vs adj. loss $1.2M in 2021.
- Q4 revenue $9.1M; net loss $2.4M; adj. loss $0.7M ($0.05/sh) vs adj. loss $1.9M in Q4 2021.
- Cash from operations $8.5M vs $6.3M prior year; balance sheet: $20M cash, $57M liabilities, $36M equity.
- Product revenue: Kristalose $15.2M, Sancuso $13.2M, Vibativ $7.5M, Caldolor $4.8M.
- Acquired Sancuso from Kyowa Kirin in 2022; new Nashville HQ; international partnerships for Vibativ and Caldolor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023006782/0001628280-23-006782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023006782/cpix-20230307.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-006782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer